The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

A cross sectional survey of 581 patients in the Aquitaine Cohort in Southwestern France was undertaken in an effort to describe lipodystrophy in protease inhibitor (PI)-naïve patients. Patients were classified as having either: peripheral wasting of the face or limbs with subcutaneous veins (LD1); peripheral abdominal adiposity, buffalo neck, mammary hypertrophy or gynacomastia (LD2) or a mixture of syndromes.

Among the cohort, 221 patients were found to have lipodystrophy, 14% of whom (n = 31) were PI-naïve. Fourteen were characterized as having LD1, with 17 showing LD2 syndromes, and 6 patients showing mixed syndromes. Twenty-two of the patients received dual nucleoside reverse transcriptase inhibitors (NRTIs); 10 patients were naïve to 3TC and 12 were naïve to d4T.

The data indicate that patients receiving NRTI therapy may develop lipodystrophy. In contrast to other data presented, the study did not find a correlation between specific medications such as d4T or 3TC and lipid abnormalities or lipodystrophy. However, the authors failed to report therapy history for the patients or duration of infection, so interpretation of the data is limited.

Abstract: Case Report of Lipodystrophy Observations in Patients Naïve of Protease Inhibitor (PI) Treatment, Aquitaine Cohort, 1999
Authored by: P. Mercie, D. Malvy, V. Daucourt, H. Dutronc, D. Lacoste, M. Dupon, J.L. Pellegrin, and R. Theibaut

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.